- Home
- CIM vs TRVI Comparison
CIM vs TRVI Comparison
Compare CIM & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIM
- TRVI
- Stock Information
- Founded
- CIM 2007
- TRVI 2011
- Country
- CIM United States
- TRVI United States
- Employees
- CIM N/A
- TRVI N/A
- Industry
- CIM Real Estate Investment Trusts
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- CIM Real Estate
- TRVI Health Care
- Exchange
- CIM Nasdaq
- TRVI Nasdaq
- Market Cap
- CIM 1.1B
- TRVI 1.1B
- IPO Year
- CIM 2007
- TRVI 2019
- Fundamental
- Price
- CIM $13.06
- TRVI $9.82
- Analyst Decision
- CIM Buy
- TRVI Strong Buy
- Analyst Count
- CIM 3
- TRVI 9
- Target Price
- CIM $15.50
- TRVI $20.72
- AVG Volume (30 Days)
- CIM 683.7K
- TRVI 2.3M
- Earning Date
- CIM 11-05-2025
- TRVI 11-05-2025
- Dividend Yield
- CIM 11.36%
- TRVI N/A
- EPS Growth
- CIM N/A
- TRVI N/A
- EPS
- CIM 1.28
- TRVI N/A
- Revenue
- CIM $312,281,000.00
- TRVI N/A
- Revenue This Year
- CIM $15.99
- TRVI N/A
- Revenue Next Year
- CIM $9.70
- TRVI N/A
- P/E Ratio
- CIM $10.14
- TRVI N/A
- Revenue Growth
- CIM 1.91
- TRVI N/A
- 52 Week Low
- CIM $9.85
- TRVI $2.36
- 52 Week High
- CIM $16.27
- TRVI $10.16
- Technical
- Relative Strength Index (RSI)
- CIM 32.06
- TRVI 65.50
- Support Level
- CIM $12.95
- TRVI $9.30
- Resistance Level
- CIM $13.57
- TRVI $10.16
- Average True Range (ATR)
- CIM 0.22
- TRVI 0.49
- MACD
- CIM -0.08
- TRVI 0.08
- Stochastic Oscillator
- CIM 8.63
- TRVI 81.60
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.